Anhydrous solvents and other reagents were purchased and used without further purification. The NMR data were obtained from Bruker 400 MHz. The purity of all compounds was ≥95%. The purity was analyzed on an Agilent LC-MS Symmetry 3 (C18 column, 4.6 x 50 mm, 5 µM) using a gradient of 5-90% acetonitrile in water containing 0.05% trifluoacetic acid (TFA) over 8 min (10 min run time) at a flow rate 2 mL/min.
S2 (tert-butyl 6-nitroindoline-1-carboxylate)
To a solution of 6-nitroindoline (1.00 g, 6.10 mmol) in CH 2 Cl 2 (50 mL) at room temperature was added triethylamine ( 147.56, 144.20, 140.37, 125.79, 118.10, 108.37, 81.34, 48.43, 28.29, 27 .73.
MS (ESI)
: m/z (M+H) + 265.2760.
S3 (tert-butyl 6-aminoindoline-1-carboxylare)
A mixture of S2 (1.46 g, 5.50 mmol) and 10% (w/w) Pd/C (0.60 g) in methanol (50 mL) was purged with H 2 for 1 min and stirred under H 2 atmosphere at room temperature for 4 h. The insolubles were filtered off through Celite pad, and the filtrate was concentrated under reduced pressure. 14, 148.53, 143.57, 125.15, 118.35, 108.32, 101.46, 80.01, 48.37, 28.52, 26.40 .
MS (ESI)
: m/z (M+H) + 235.3062. S4 (ethyl 6-bromo-4-(1-(tert-butoxycarbonyl)indolin-6-ylamino)quinoline-3-carboxylate) 4 To a solution of ethyl 6-bromo-4-chloroquinoline-3-carboxylate (0.22 g, 0.71 mmol) in 1,4-dioxane at room temperature added compound S3 (0.17 g, 0.71 mmol).
The resulting solution was heated to 110°C in a sealed tube for 6 h. After the mixture was cooled to room temperature, a solution of aqueous NaOH (1.00 N) was added to neutralize the mixture before being diluted with water and extracted with ethyl acetate.
The combined organic phases were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to furnish the crude product S4.
S5 (4-(indolin-6-ylamino)-6-methylquinolin-3-yl)methanol
To a solution of crude product S4 (0.31 g, 0.60 mmol) in EtOH (20 mL), NaBH 4 (0.11 g, 3.00 mmol) was added. The resulting solution was stirred at 40 o C for 12 h before being quenched with saturated aqueous NH 4 Cl and filtered through Celite pad.
The filtrate was concentrated under reduced pressure, and the residue was dissolved in EtOAc and brine. After separation, the organic layer was dried over anhydrous MgSO 4 , filtered and concentrated to afford the crude product, which was dissolved in CH 2 Cl 2 (20 mL), then TFA (0.68 g, 6 mmol,) was added. The mixture was stirred at room temperature for 6 h. A solution of saturated sodium bicarbonate was added.
After separation, the organic layer was dried over anhydrous MgSO 4 , filtered and concentrated to afford the crude product S5.
S6 4-(indolin-6-ylamino)-6-methylquinoline-3-carbaldehyde
To a solution of crude product S5 (0.23 g, 0.60 mmol）in CH 2 Cl 2 (25 mL) at room temperature, MnO 2 (0.22 g, 2.50 mmol) was added. After 6 h, the reaction mixture was filtered through Celite pad. The filtrate was concentrated under reduced pressure to afford the crude product S6.
S7 1-(indolin-6-yl)-9-methylbenzo[h][1,6]naphthyridin-2(1H)-one
To a solution of crude product S6 (0.22 g, 0.60 mmol) in dry EtOH (30 mL) at room temperature, Cs 2 CO 3 (0.46 g, 1.41 mmol) and triethyl phosphonoacetate (0.21 g, 0.95 mmol) was added. The resulting mixture was heated to 110 o C in a sealed tube for 12 h before being cooled to room temperature. Upon removal of the solvents, the residue was diluted with water followed by extraction with EtOAc. The combined organic phases were dried over anhydrous Mg 2 SO 4 , filtered and concentrated. The compound S8 (86.00 mg, 0.22 mmol) was dissolved in dry THF (5 mL) and stirred at 0 °C for 20 min. Diisopropylethylamine (0.10 g, 0.8 mmol) was added. After 5 min, acryloyl chloride (37.00 mg, 0.40 mmol) was added, and the reaction mixture was stirred for another 5 min at 0 °C. The reaction mixture was then warmed up to room temperature and continued to stir for 1 h under Argon. THF was evaporated.
EtOAc and water were added. The layers were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed three times with a NaHCO 3 solution (4%). The organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by chromatography to give pure QL47 as an off-white solid, 5.00 mg (51% yield, two steps 
S9 (E)-1-(1-(4-bromobut-2-enoyl)indolin-6-yl)-9-(1-methyl-1H-pyrazol-4-yl)-1-(1 -propionylin-6-yl)benzo[h][1,6])naphthyridin-2(1H)-one)
To a solution of compound S8 (12.00 mg, 0.03 mmol) in dry DMF (2 mL) cooled in an ice-water bath, diisopropylethylamine (11.61 mg, 0.09 mmol) was added. 
QL47B (E)-N-(16-(6-(9-(1-methyl-1H-pyrazol-4-yl)-2-oxobenzo[h][1,6]naphthy ridin-1(2H)-yl)indolin-1-yl)-16-oxo-3,6,9-trioxa-12-azahexadec-14-enyl)-5-(2-oxo hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide)
To a solution of compound S9 (8.00 mg, 0.02 mmol) in DMF (2 mL) in an ice-water bath, biotin-PEG3-amine (8.36 mg, 0.02 mmol) was added. After stirring at 0 ℃ for 10 h, water was added, and the mixture was extracted with CHCl 3 /i-PrOH In vitro target occupation assay (Fig. 1D) Cell lysates from Ramos cells were treated with different concentrations of covalent inhibitor QL47 on ice for 4 hours. 5 µM biotinylated covalent probe (QL47B) was then added and lysates were incubated for another 4 hours. Uninhibited BTK was then captured by adding 50 µl Streptavidin agarose resin suspensions (Pierce) followed by an incubation for 1 hour. The resin was then spun down, washed briefly with 1X PBS buffer, and then resuspended in protein sample buffer for Western blot analysis.
Chemiluminescence was quantified using ImageJ software, and normalization to an untreated control sample allowed the determination of the % BTK occupancy.
QL47B cell permeability assay (SFig. 3)
Ramos cells were first treated with drugs at indicated concentrations for four hours, washed with 1X PBS buffer to remove excess drugs in the medium, and harvested for 9 cell lysate preparation. Cell lysates were then incubated with Streptavidin agarose beads for 4 hours at 4°C. Next, the beads were spun down and washed with 1X PBS buffer. Bound proteins were then eluted with protein sample buffer after boiling and subjected to Western blot analysis.
QL47 Induced BTK Degradation (Fig. 2E, F and SFig. 9)
Generation of HEK293T-BTK stable cell lines Retroviral expression vectors were constructed by inserting full-length wild-type and C481S mutant BTK coding regions into a pMSCV-puro vector (Clontech) that was modified by inserting a 3XFLAG sequence at the 3' end of the multi-cloning sites.
HEK293T cells stably expressing BTK-WT-FLAG and BTK-MT-FLAG were made by co-transfecting the BTK-containing MSCV vectors together with two helper plasmids using Fugene 6 (Roche) for 48 hours. After that cells were selected in DMEM medium containing 2 µg/ml of puromycin for 48 hours. Selected cell lines were maintained in DMEM medium supplemented with 1 µg /ml puromycin.
BTK degradation in HEK293T cells
HEK293T-BTK-WT and HEK293T-BTK-MT stable cells were plated on 60 mm plates on the first day for attachment. On the second day DMSO, QL47 (1 µM) or QL47R (1 µM) was added to each well and incubated for 4 hours before being washed out and replaced with medium containing DMSO or 50 µg/ml of CHX for 12 or 16 hours. Cells were then washed in 1X PBS buffer and lysed in cell lysis buffer.
BTK antibody and tubulin antibody (Cell signaling Technology) were used for immunoblotting. Quantification was done using ImageJ software.
BTK degradation in Ramos cells
Ramos cells in 10% FBS/RPMI were treated with 1 µM of different BTK inhibitors (QL47, PCI 32765, CGI-1746) for 4 hours before washout and replaced with 50 µg/ml of CHX for 12 or 24 hours. Cells were then washed in 1XPBS buffer and lysed in cell lysis buffer. BTK antibody and tubulin antibody (Cell signaling Technology)
